Skye Bioscience Announces Inducement Grant Under Nasdaq Listing Rule
SAN DIEGO — Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biopharmaceutical company dedicated to exploring new therapeutic pathways for metabolic health, has revealed that its Board of Directors has granted a non-qualified stock option award to purchase 40,000 shares of common stock to a newly hired non-executive employee. This award is part of the Company’s 2024 Inducement Equity Incentive Plan and was provided as a material incentive for the employee to join Skye, in accordance with Nasdaq Listing Rule 5635(c)(4).
Overview of the 2024 Inducement Plan
The 2024 Inducement Plan is specifically designed for granting equity awards to individuals who have not previously been employees of Skye or who have experienced a bona fide period of non-employment. These grants are intended to serve as a significant incentive for these individuals to start their employment with Skye, in line with Nasdaq Listing Rule 5635(c)(4). The stock options come with an exercise price of $5.28 per share, reflecting the closing price of Skye’s common stock on The Nasdaq Global Select Market. The shares linked to these stock options will vest over a four-year period. Specifically, 25% of the shares will become available on the one-year anniversary of the vesting commencement date, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent upon the employee's continued employment with Skye during those vesting periods. The stock options will adhere to the guidelines outlined in the 2024 Inducement Plan and a corresponding stock option agreement.
About Skye Bioscience
Skye Bioscience is committed to discovering and developing groundbreaking therapeutic pathways that aim to enhance metabolic health through next-generation molecules designed to modulate G-protein coupled receptors. The company's strategic focus leverages biological targets that have demonstrated significant human proof of mechanism, paving the way for the creation of first-in-class therapeutics with unique clinical and commercial benefits. Recently, Skye launched a Phase 2 clinical trial aimed at treating obesity. This trial is assessing nimacimab, a negative allosteric modulator antibody that inhibits CB1 peripherally. The study will compare the effects of nimacimab administered alone versus its administration in conjunction with a GLP-1R agonist.
Contact Information
If you have any questions regarding investor relations, please reach out to:
Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266
Media Inquiries
Contact: LifeSci Communications, Michael Fitzhugh
Email: mfitzhugh@lifescicomms.com
Phone: (628) 234-3889
Frequently Asked Questions
What is the significance of the stock option grant by Skye?
The stock option grant is a strategic move to attract new talent to Skye, aligning the interests of employees and shareholders.
How does the 2024 Inducement Plan benefit Skye Bioscience?
This plan enables Skye to provide competitive compensation packages to new hires, thereby strengthening their recruitment efforts.
What is nimacimab and how is it being used in trials?
Nimacimab is an antibody that acts as a negative allosteric modulator targeting CB1, and it is currently being tested in a Phase 2 clinical trial focused on obesity treatment.
What are the terms of the stock options granted?
The stock options feature an exercise price of $5.28 per share and follow a four-year vesting schedule that depends on the employee's continued employment.
How can interested parties connect with Skye Bioscience?
Interested individuals can connect with Skye through their official website and social media platforms for updates and inquiries.
